Breaking News

Lilly to Invest $450M at Manufacturing Site in Research Triangle Park

Expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly's incretin products.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eli Lilly and Company has unveiled plans to invest an additional $450 million and create at least 100 new jobs to expand its manufacturing capacity at the company’s Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly’s incretin products that treat diabetes. “As we move into 2023, Lilly is focused on finding innovative solutions to meet the growing demand for our...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters